Evaluation of a peer support group programme for vulnerable host population and refugees living with diabetes and/or hypertension in Lebanon: a before-after study
Our study showed mixed results. In terms of reach, over 50% of those approached consented to participate. Regarding the impact on PROMs, we observed improvements in most outcomes; however we found some statistical evidence only for some. We did not find strong statistical evidence of improvement in clinical outcomes compared to the control group. Differences between the two waves may be due to differences in the populations, the way the intervention was delivered, or the individuals implementing it. Additionally, as multiple outcomes were measured, some observed differences may be due to chance. We demonstrated that it is feasible to implement PSGs in humanitarian settings and found some statistical evidence of improvement in quality of life. Further studies should assess the implementation and impact of PSGs in ways that are well accepted by local stakeholders (including humanitarian actors and people living with NCDs) and are potentially amenable to scale-up.
Authors
- Éimhín Ansbro (ORCID: https://orcid.org/0000-0002-2291-1652)
- Lars Bruun Larsen (ORCID: https://orcid.org/0000-0001-9120-4751)
- Leah Anku Sanga (ORCID: https://orcid.org/0000-0003-1604-0771)
- Tim Clayton (ORCID: https://orcid.org/0000-0002-1266-3288)
- Jasmin Lilian Diab (ORCID: https://orcid.org/0000-0003-4158-7728)
- Benjamin Schmid (ORCID: https://orcid.org/0000-0002-7396-4404)
- Ali Ibrahim (ORCID: https://orcid.org/0000-0002-7323-177X)
- Pablo Perel (ORCID: https://orcid.org/0000-0002-2342-301X)
- Carla Njeim
- Rima Kighsro Naimi
- Jytte Roswall
Institutions
- London School of Hygiene & Tropical Medicine (GB)
- Lebanese American University (LB)
Publication Details
- Journal
- Conflict and Health
- Published
- 2025-01-29
- DOI
- https://doi.org/10.1186/s13031-025-00646-4
- Primary Topic
- Chronic Disease Management Strategies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novo Nordisk